Implications of brain imaging for the management of schizophrenia

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 3, 1998, Pages

  Nyberg, Svante ^a   Nilsson, Ulrika ^a   Okubo, Yoshiro ^a   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antipsychotic drugs; Dopamine D2 receptor occupancy; Extrapyramidal symptoms; Positron emission tomography; Schizophrenia; Serotonin (5 HT(2A)) receptor occupancy

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE; SERTINDOLE;

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCHIZOPHRENIA;

EID: 0031798520     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199803003-00003     Document Type: Article

References (44)

1. Ayd FJ Jr (1961). A survey of drug-induced extrapyramidal reactions. JAMA 175:1054-1060.
2. Baldessarini RJ, Cohen BM, Teicher MH (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79-91.
3. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
5. Casey DE (1989). Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 25:457-459.
6. 2 dopamine receptor binding in the living human brain by PET. Science 231:258-261.
7. 2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708.
8. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
9. 2 receptor binding in risperidone-treated patients. J Clin Psychopharmacol 15 (suppl 1):19S-23S.
10. 2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int Clin Psychopharmacol 12 (suppl 1):S3-S7.
11. Gerlach J (1991). New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 17:289-309.
12. Gilbert PL, Harris J, McAdams LA, Jeste DV (1995). Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 52:173-188.
13. Hansen TE, Casey DE, Hoffman WF (1997). Neuroleptic intolerance. Schizophr Bull 23:567-582.
14. Hyttel J, Nielsen JB, Nowak G (1992). The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies). J Neural Transm (Gen Sect) 89:61-69.
15. 2 antagonistic properties. J Pharmacol Exp Ther 244:685-693.
16. Kane JM, Marder SR (1993). Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287-302.
17. 1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacol 119:1-8.
18. Kasper S (1998) How much do novel antipsychotics benefit the patients? Int Clin Psychopharmacol 13 (suppl 3):S71-S77.
19. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988). Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661-670.
20. Marder SR, Meilbach RC (1994). Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
21. Meltzer HY (1989). Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27.
22. Meltzer HY (1991). The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287.
23. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392.
24. Moore NA, Tye NC, Axton MS, Risius FC (1992). The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262:545-551.
25. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110:365-367.
26. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449.
27. 2 receptor occupancy in olanzapine treated patients. Arch Gen Psychiatry.
28. 2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology 110:265-272.
29. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152:173-178.
30. 2 dopamine receptor occupancy and antipsychotic drug plasma levels in man. Int Clin Psychopharmacology 10 (suppl 3):81-85.
31. 2 receptor occupancy induced by risperidone in schizophrenic patients [abstract]. In: 35th American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, December 1996. Nashville (TN): American College of Neuropsychopharmacology.
32. 2 receptor occupancy: a PET study in haloperidol-treated patients. Psychiatry Res 67:163-171.
33. 2 dopamine receptor availability after discontinuation of haloperidol decanoate: preliminary findings. Arch Gen Psychiatry 54:953-958.
34. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacol 16:1-7.
35. Peuskens J (1995). Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726.
36. Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembøl HL, Meier E, et al. (1991). Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239-250.
37. Schotte A, Janssen PMF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
38. Sedvall G, Farde L (1995). Chemical brain anatomy in schizophrenia. Lancet 346:743-749.
39. Skarsfeldt T (1992). Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10:25-33.
40. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB (1997). Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12 (suppl 1):S29-S35.
41. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457-465.
42. Volavka J, Cooper TB, Meisner M, Bitter I, Czobor P, Jaeger J (1990). Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Psychopharmacol Bull 26:13-17.
43. Volavka J, Cooper TB, Czobor P, Meisner M (1995). Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 52:837-845.
44. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154:782-791.